prostatic cancer
Conditions
Interventions
High risk metastatic hormone sensitive prostate cancer:NA
Sponsors
Zhongnan Hospital of Wuhan University
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: (1) Prostate adenocarcinoma was diagnosed by pathology; (2) High risk metastatic prostate cancer was considered by imaging examination including pmsa-pet and bone scan: Gleason score = 8, there were three or more lesions in bone scan, or there were measurable visceral metastasis except lymph node metastasis; (3) No previous anti-tumor treatment including androgen deprivation therapy; (4) ECOG score = 2; (5) Immunohistochemical ar-v7 staining was positive in prostate cancer; (6) Patients who can tolerate androgen deprivation therapy, docetaxel chemotherapy and abiraterone therapy.
Exclusion criteria
Exclusion criteria: (1) Patients with life expectancy less than 1 year; (2) Patients who have serious mental illness or are unable to cooperate with treatment or follow-up due to other reasons; (3) Patients who fail to treat according to the doctor's instructions; (4) Patients with other neoplastic diseases; (5) Prostate cancer with pathological types other than adenocarcinoma; (6) Patients with severe allergy to gonadotropin releasing hormone (GnRH) analogues; (7) Blood testosterone could not reach castration level (= 50ng/ml) during treatment; (8) Patients receiving immunosuppressive therapy or with immune deficiency diseases; (9) Patients with severe liver function impairment (child Pugh grade C); (10) Patients with severe renal function injury who need long-term dialysis treatment; (11) Patients with severe myelosuppression and severe neutropenia; (12) Participate in other clinical studies from 30 days before enrollment to the completion of this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival; | — |
Countries
China
Contacts
Public ContactHua Xu
Outcome results
None listed